Abstract

Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects
G Wensing ... J Kuhlmann
Int. Journal of Clinical Pharmacology and Therapeutics | VOL. 43
G Wensing, et. al.G Wensing ... J Kuhlmann
01 May 2005
THU0270 European ankylosing spondylitis (AS) infliximab cohort (EASIC) long-term extension: Efficacy and safety of infliximab over a time period of more than 7 years in patients with AS
G.R Burmester ... J Brandt
Annals of the Rheumatic Diseases | VOL. 71
G.R Burmester, et. al.G.R Burmester ... J Brandt
01 Jun 2013
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Filip Van Den Bosch ... Martin Rudwaleit
Arthritis Research & Therapy | VOL. 12
Filip Van Den Bosch, et. al.Filip Van Den Bosch ... Martin Rudwaleit
01 Jan 2009
Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease
Yuji Tohda ... Toru Soutome
Current Medical Research and Opinion | VOL. 32
Yuji Tohda, et. al.Yuji Tohda ... Toru Soutome
18 Feb 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers